NHLBI working group recommendations to reduce lipoprotein (a)-mediated risk of cardiovascular disease and aortic stenosis
S Tsimikas, S Fazio, KC Ferdinand… - Journal of the American …, 2018 - jacc.org
Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …
PCSK9: from basic science discoveries to clinical trials
MD Shapiro, H Tavori, S Fazio - Circulation research, 2018 - ahajournals.org
Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now
common parlance among scientists and clinicians interested in prevention and treatment of …
common parlance among scientists and clinicians interested in prevention and treatment of …
The evolving future of PCSK9 inhibitors
RS Rosenson, RA Hegele, S Fazio… - Journal of the American …, 2018 - jacc.org
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …
mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies …
The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies
AD Sniderman, S Tsimikas, S Fazio - Journal of the American College of …, 2014 - jacc.org
The severe hypercholesterolemia phenotype includes all patients with marked elevation of
low-density lipoprotein cholesterol (LDL-C) levels. The most common cause is autosomal …
low-density lipoprotein cholesterol (LDL-C) levels. The most common cause is autosomal …
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
Proprotein convertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein
receptor levels and LDL-cholesterol levels. Loss-of-function mutations in PCSK9 gene are …
receptor levels and LDL-cholesterol levels. Loss-of-function mutations in PCSK9 gene are …
Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein (a)
MS Safarova, PM Moriarty - Current Atherosclerosis Reports, 2023 - Springer
Abstract Purpose of Review Familial hypercholesterolemia (FH) and hyperlipoproteinemia
(a) are relatively common disorders, posing a significant health burden due to increased risk …
(a) are relatively common disorders, posing a significant health burden due to increased risk …
[HTML][HTML] Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs
C Stefanutti, U Julius, GF Watts, M Harada-Shiba… - Journal of clinical …, 2017 - Elsevier
Background Despite advances in pharmacotherapy of lipid disorders, many dyslipidemic
patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular …
patients do not attain sufficient lipid lowering to mitigate risk of atherosclerotic cardiovascular …
PCSK9 modulates the secretion but not the cellular uptake of lipoprotein (a) ex vivo: an effect blunted by alirocumab
EF Villard, A Thedrez, J Blankenstein, M Croyal… - JACC: Basic to …, 2016 - jacc.org
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor
alirocumab modulates lipoprotein (a)[Lp (a)] plasma levels, the authors performed a series …
alirocumab modulates lipoprotein (a)[Lp (a)] plasma levels, the authors performed a series …
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
R Schulz, KD Schlüter, U Laufs - Basic research in cardiology, 2015 - Springer
The proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising
treatment target to lower serum cholesterol, a major risk factor of cardiovascular diseases …
treatment target to lower serum cholesterol, a major risk factor of cardiovascular diseases …
PCSK9 association with lipoprotein (a)
Rationale: Lipoprotein (a)[Lp (a)] is a highly atherogenic low-density lipoprotein–like particle
characterized by the presence of apoprotein (a)[apo (a)] bound to apolipoprotein B …
characterized by the presence of apoprotein (a)[apo (a)] bound to apolipoprotein B …